Vasopressin

Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors[1][2][3].

O=C([C@H]1NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CSSC1)N)=O)CC2=CC=C(C=C2)O)=O)CC3=CC=CC=C3)=O)CCC(N)=O)=O)CC(N)=O)=O)N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(NCC(N)=O)=O)=O

[1]Baribeau DA, et, al. Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci. 2015 Sep 24;9:335.|[2]Ramos L, et, al. Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology. 2013 Oct;38(11):2249-59.|[3]Gal CSL, et, al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.Endocrinology. 2023 Jan 9;164(3):bqac217.|Endocrinology. 2023.|Eur J Pharmacol. 10 September 2022, 175262.|SSRN. 2023 May 30.|Biochem Pharmacol. 2022 Sep 29;115265.|BMC Pulm Med. 2021 Jun 5;21(1):189.|Chemosphere. 2021 Apr;269:128776.|Front Neurosci. 2022 Mar 25;16:838942.|Front Pharmacol. 2019 Nov 15;10:1380.|J Cell Mol Med. 2022 Oct 14.|Research Square Preprint. 2023 Sep 11.|The Pharma Innovation. 2020; 9(7): 553-560.